RxDoctor Payments Data

Amanda Achilles

Optometrist · Albuquerque, NMNPI 1518415660

Payments from drug & device makers

$543in general payments, 2019–2025

Across 17 payments — averaging $31.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb, A Division Of Bausch Health US, LLC$240
  • AbbVie$143
  • Alcon$79
  • Bausch & Lomb Americas Inc.$36
  • Coopervision Inc.$23
  • Harrow Eye, LLC$22

What the payments were for

  • Food & beverage$543100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$543 in reported general payments places this provider in the 55th percentile of 228 optometrist providers in New Mexico.

See all optometrist providers in New Mexico

Medicare billing

Part B allowed, 2024
$168,690
Medicare patients
974
Services billed
2,079

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost312$156,729
RestasisCyclosporine39$63,275
Latanoprost1,895$36,442
Cyclosporine56$22,948
XiidraLifitegrast21$20,741
Travoprost105$16,052
Restasis MultidoseCyclosporine15$9,425
Timolol Maleate409$8,020
Alphagan PBrimonidine Tartrate19$7,576
Brimonidine Tartrate311$6,521
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat348$5,547
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol26$3,383
Dorzolamide Hcl109$2,163
Prednisolone Acetate52$1,862
ErythromycinErythromycin Base67$961

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Restasis Multidose, Alphagan P$143$237,005385 claims
Bausch & Lomb Americas Inc.Xiidra$36$20,74121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 228 optometrist providers in New Mexico.

Other optometrist in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →